At the end of last year, when the Tax Cuts and Jobs Act of 2017 looked like it would pass Congress and then dramatically drop federal income tax rates, APGA spotlighted Federal Energy Regulatory Commission (FERC)’s responsibility to address that impact on interstate pipeline rates. APGA was Continue Reading
Estate Planning and Administration in the Digital Age
As estate planners and tax advisors, when we think of estate planning and administration, certain assets come to mind. We typically think of real estate, vehicles, jewelry, and other tangible personal property. We might also think of financial assets, such as cash, stocks, and bonds. Those Continue Reading
FIRRMA Becomes Law, Reforming CFIUS, Export Controls, and Forever Changing Diligence in Foreign Direct Investment and Structuring of Public and Private Equity Deals
In June 2018, the White House outlined the threats posed by China’s investment in and acquisition of US companies, noting that China is engaged in "state-sponsored IP theft through physical theft, cyber-enabled espionage and theft, evasion of US export control laws, and counterfeiting and piracy." Continue Reading
Entering the US Market: Legal Hurdles That Manufacturers Must Overcome
From design to delivery, a manufacturer has so much to consider when selling a product in the United States. The US government, as well as independent agencies, police nearly every facet of product development, and the regulations are constantly changing in light of both technological and scientific Continue Reading
Notice Poster for New Jersey’s Earned Sick Leave Law Released by Department of Labor for Use Starting on October 29
The New Jersey Department of Labor and Workforce Development (“NJDOL”) has released its notice poster pursuant to the Earned Sick Leave Law, N.J.S.A. 34:11D-1 et seq. (the “Law”), that takes effect on October 29, 2018. This notice, which is available in English and multiple other languages, has to Continue Reading
NJ Supreme Court Issues Another Landmark Decision in In re Accutane, this Time Regarding Choice-of-Law and the Presumption of Adequacy for FDA-Approved Warnings
Nearly two months to the day after the New Jersey Supreme Court issued a landmark decision in the In re Accutane® Litigation incorporating the Daubert factors into New Jersey law, the court issued another major decision in the same litigation that left no doubt about the strength of the presumption Continue Reading
New Jersey Supreme Court’s Landmark Accutane Decision Raises the Bar for Expert Testimony
Not only does the New Jersey Supreme Court’s decision in In re: Accutane pave the way to ending a fifteen-year litigation, it sends a clear message to trial courts regarding the critical importance of their role as the gatekeepers of expert testimony in civil cases. The landmark decision adopted the Continue Reading
Increased Transparency to Continuing Disclosure Requirements
In an effort to increase transparency and protect holders of municipal securities, on August 20, 2018, the US Securities and Exchange Commission (the “SEC” or the “Commission”) added two new requirements to the continuing disclosure requirements of Rule 15c2-12 of the Securities Exchange Act (the Continue Reading
McCarter Plays Key Role in New Jersey Supreme Court’s Landmark In re: Accutane Decision Regarding Expert Admissibility Standards
Until now, the perception that New Jersey law on expert admissibility was weaker than the Daubert standard used in federal courts and many other states—combined with New Jersey being home to so many pharmaceutical and medical technology companies—made New Jersey a magnet for mass tort litigation Continue Reading
New Jersey Biotechnology Task Force Recommends Angel Investor Tax Credit Program Expansion
Good news for investors and entrepreneurs: The New Jersey Biotechnology Task Force (Task Force)[1] has published its final report and recommendations to expand the Angel Investor Tax Credit Program with the goal of incentivizing companies in the life sciences industry to either remain in or relocate Continue Reading